Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: McCaughan, Georgia; Fulham, Michael; Mahar, Annabelle; Soper, Judy; Hong, Angela; Stalley, Paul; Tattersall, Martin; Bhadri, Vivek
• Is Part Of: Journal of hematology & oncology. Volume 9:Issue 1(2016)
• Page Start: 1
• Page End: 5
• Publication Date: 2016-12
• Subjects: Ewing sarcoma -- Immunotherapy -- Anti-programmed cell death-1 antibody -- Case report; Hematology -- Periodicals; Oncology -- Periodicals; Blood -- Diseases -- Periodicals; 616.994
• DOI: 10.1186/s13045-016-0278-x
• Languages: English
• ISSNs: 1756-8722

Abstract

Abstract Background Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor. Case presentation In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade. Conclusions To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.